# Jonathan W. Goldman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jonathan-w-goldman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 35,087 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 68 |
| i10-index | 194 |
| Last Known Institution | Santa Monica College |
| OpenAlex ID | https://openalex.org/A5036134937 |
| ORCID iD | 0000-0002-4925-8243 |
| Works | 792 |

## Researcher papers

Showing 12 of 21.

- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial](https://scholariq.org/papers/previous-radiotherapy-and-the-clinical-activity-and-toxicity-of-pembrolizumab-in/)
- [Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study](https://scholariq.org/papers/nivolumab-plus-ipilimumab-as-first-line-treatment-for-advanced-non-small-cell/)
- [Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-altered-thyroid-cancers/)
- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/osimertinib-with-or-without-chemotherapy-in-i-egfr-i-mutated-advanced-nsclc/)
- [Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/rociletinib-in-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients](https://scholariq.org/papers/circulating-tumour-dna-profiling-reveals-heterogeneity-of-egfr-inhibitor/)
- [Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)

## Researcher university

- [Santa Monica College](https://scholariq.org/institutions/santa-monica-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.